Drug Discovery

Biotech Videos 

The 2021 Creative Biolabs Scholarship Acceptance Speech
https://www.creative-biolabs.com/scholarship-program.html

The 2021 Creative Biolabs Scholarship Acceptance Speech

Teach Me in 10

In some patients, the rapid antidepressant action of ketamine can last for days, or even weeks. This, says Dr. Lisa Monteggia, is incredible for a drug that is cleared from the body very quickly. Over recent years, The Monteggia laboratory at the University of Vanderbilt has been investigating the molecular mechanisms that underly this rapid action.  In this Teach Me in 10, Dr. Monteggia outlines some of the key discoveries that her team have made, particularly in relation to ketamine, neuroplasticity and neuroreceptors.

Ketamine as an Antidepressant With Dr. Lisa Monteggia

BÜCHI Labortechnik AG

Join BUCHI application chemist, Björn Brodbeck, as he explains how to correct common peak malformations, including:
- peak fronting
- peak tailing 
- peak splitting. 

Benefit from essential theory, practical information and beneficial tips in a compact chromatography mini-tutorial perfect for your coffee break. Achieve optimal peak shapes for optimal separation power for your flash chromatography or prep HPLC applications.

Perfect chromatography peaks: Clever solutions to peaks with fronting, tailing or splitting

Mutant library

Creative Biogene provides world-class packaging services for a variety of viral types using our QVirusTM platform. Creative Biogene's state-of-the-art facilities and highly experienced staff are available in order to assist in all areas of virus vector design and construction, as well as the generation of the virus in a quick turnaround. Our custom viral services are highlighted by a consistent high titer and large delivery viral counts.

https://www.creative-biogene.com/Services/Custom-Viral-Service

Custom Viral Service

Oncotarget

Volume 11, Number 21 of Oncotarget reported that eligible patients with stable or responding mPDA after 6 months on chemotherapy were randomized 1:1 to metformin alone or with rapamycin, stratified by prior treatment with FOLFIRINOX. Metformin +/ rapamycin maintenance for mPDA was well-tolerated and several patients achieved stable disease associated with exceptionally long survival.

Dr. Dung T. Le from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21287 said, "Pancreatic ductal adenocarcinoma (PDA) is aggressive cancer with high mortality at all stages and limited treatment options in the advanced setting."

Metformin is an antidiabetic drug in the biguanide class of agents which inhibits mTOR complex 1 primarily through AMP-kinase activation.

A synergistic effect of the combination of metformin with rapamycin was suggested by preclinical studies demonstrating enhanced inhibition of mTOR in a pancreatic cancer cell line and better growth inhibition of pancreatic cancer cells in a xenograft tumor model with the combination than either agent alone.

Based on this, they conducted an exploratory study of metformin with or without rapamycin in patients with mPDA in the maintenance setting.

The Le Research Team concluded in their Oncotarget Research Article, "the administration of metformin with or without rapamycin in patients with mPDA who achieve a response to chemotherapy is well-tolerated and was associated with better than expected overall survival in this study. Additional studies are needed to prospectively evaluate the role of these agents compared to a maintenance chemotherapy or observation only approach."

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27586

DOI - https://doi.org/10.18632/oncotarget.27586

Full text - https://www.oncotarget.com/article/27586/text/

Correspondence to - Dung T. Le - dle@jhmi.edu

Keywords - pancreatic cancer, mTOR inhibition, maintenance therapy, metformin

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/c/OncotargetYouTube/
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Author Insight: Exploratory Study of Metformin and Rapamycin as Maintenance Therapy

What is a cannabis testing laboratory? What kind of testing services do labs provide? What equipment is found in a cannabis testing lab? All of these questions  (and more!) are addressed in this Analytical Cannabis special episode of Teach Me in 10, where we're joined by Jini Curry, cannabis laboratory director.

What is a Cannabis Testing Lab? With Jini Curry

Elixirgen Scientific

Visit our website to find out more: https://www.elixirgensci.com/

Mohamed Hassan Farah, Ph.D.
Associate Professor of Neurology, The Johns Hopkins University School of Medicine

Dr. Mohamed H. Farah is an associate professor in the department of neurology as well as the department of neuroscience at The Johns Hopkins University School of Medicine. Dr. Farah received his undergraduate degree in biochemistry from Virginia Tech in Blacksburg, Virginia. He earned his Ph.D. in neuroscience from the University of Michigan in Ann Arbor, Michigan and completed a postdoctoral fellowship in the department of pathology at The Johns Hopkins University School of Medicine. The Mohamed Farah Lab studies axonal regeneration in the peripheral nervous system. His team is currently engaged in interactions of target tissues and human axon from IPSC-derived neurons.


Muzammil Ahmad, Ph.D.
Scientist III, Elixirgen Scientific Inc.

Dr. Muzammil Ahmad joined Elixirgen Scientific in 2016. He has a Ph.D. in Biotechnology from the National Centre for Cell Science (NCSS) in India, and completed a postdoctoral fellowship at the NIH National Institute on Aging. He has over 15 years experience in the biotech and pharmaceutical research industries. Dr. Ahmad works in Research & Development at Elixirgen Scientific, where he supervises a team of Ph.D. scientists and lab assistants that develop and fine-tune commercial iPSC-derived differentiation kits for a myriad of cell types. Dr. Ahmad specializes in creating intuitive and easy-to-follow protocols to ultimately save clients’ time and increase their efficiency so they can focus on achieving their research goals.

Webinar: Human iPSC-Derived Neuromuscular Research & Transcription factor-based iPSC Differentiation

Sekisui XenoTech

Presenter: Maciej Czerwinski, Ph.D., SEKISUI XenoTech Director of Scientific Consulting

Abstract:
The importance of glucuronidation for metabolism of xenobiotics in humans is illustrated by the abundance and broad tissue distribution of the enzymes, the diversity of substrates and reactions catalyzed, as well as a number of distinctive UGT enzymes and their genetic polymorphisms. The involvement of UGTs in metabolism of new drug candidates will be presented as it underscores the enzymes’ importance from regulatory and safety perspectives.

Basic biochemical characteristics of UGTs will be reviewed and examples of major forms of glucuronides formed in humans will be presented. Distinctive properties of acyl-glucuronides and their significance for drug-drug interactions will be highlighted. Factors contributing to underprediction of UGTs’ in vivo contributions to the metabolism of xenobiotics will also be covered. Laboratory approaches aimed at improving these predictions will be covered, as well.

Key concepts discussed in this webinar will include:
 - Significance of UGT-mediated metabolism in drug development process
 - Consequences of formation of acyl-glucuronides
 - Underprediction of in vivo UGT-mediated metabolism

Request a copy of the slides: https://www.xenotech.com/about/events/webinar-role-of-udp-glucuronosyltransferases-in-drug-metabolism-and-drug-drug-interactions/
Questions, comments and requests: https://www.xenotech.com/contact/
More information on our research services and test systems: https://www.xenotech.com
Other previously aired webinars: https://www.xenotech.com/access-adme-research-resources/resource-type/webinar/
Upcoming webinar notifications: https://www.xenotech.com/contact/newsletter-sign-up/
Request a webinar topic: https://www.xenotech.com/contact/webinar-seminar-request/

About the Presenter:
Dr. Maciej Czerwinski serves as a Director in the Scientific Consulting department at SEKISUI XenoTech. He received his Ph.D. from the University of Maryland at Baltimore Medical School in the Department of Pathology. Dr. Czerwinksi conducted his doctoral thesis research in the Laboratory of Dr. Frank Gonzalez at the National Cancer Institute in Bethesda, followed by a post-doc at the Department of Pharmaceutics, the University of Washington in Seattle. He has been with SEKISUI XenoTech since 1999 and guides the development of products and services for the in vitro analysis of drug safety. Dr. Czerwinski designed a patented method to analyze the in vitro cytokine-mediated drug-drug interactions between biologics and small molecule drugs, and he is also the inventor of SEKISUI XenoTech’s CryostaX single-freeze pooled hepatocytes.

The Important Role of UDP Glucuronosyltransferases in Drug Metabolism and Drug Drug Interactions

BioTek Instruments

BioTek Synergy H1 is a modular multimode microplate reader, with monochromator-based optics and filter-based optics. The patented Hybrid Technology offers flexibility and sensitivity across a broad range of applications. The modular platform allows upgrading to expand functionality as your laboratory workflows change.

Synergy H1 offers continuously variable bandwidth monochromators for fluorescence excitation and emission wavelength selection. Fluorescence bandwidth can be set between 9 and 50 nm, in 1 nm increments, allowing users to fully optimize reader settings to drive the best assay performance compared to fixed bandwidth systems.

Products:
 
BioTek Synergy H1 Hybrid Multimode Reader
www.biotek.com/synergyh1

BioTek BioStack Microplate Stacker
www.biotek.com/biostack

BioTek Gen5 Software
www.biotek.com/gen5

BioTek Quantitative Assay Apps
www.biotek.com/products/software-software-apps/quant-assay-apps/

Drug Discovery

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.